“I believed in the power of PhysioPD when I first saw it twenty-five years ago, I’ve had a passion for it ever since, and now we have enough experience that I know it works.”


About Rosa & Co
Rosa was founded in 2002 and remains an employee-owned, science-focused, and client-friendly firm. Today, Rosa is the worldwide commercial leader in PhysioPD-style Research, with comprehensive basic biology and therapeutic experience, industry-leading modeling expertise, and repeat research engagements with a majority of the Top 20 pharmaceutical companies.
Rosa's ForecastMD Platforms, which offers a credible methodology for determining expected physician uptake for healthcare products, was started by Bill Brastow, Ph.D., in 2005. Our models have helped shape first-in-class markets including novel therapy combinations for HIV and molecular diagnostic tests for Oncology.
Rosa’s staff bring more than a century of aggregate experience in applying modeling to the inherent challenges faced by drug developers and have authored hundreds of scientific posters, conference presentations, relevant patents, and peer-reviewed publications.
Rosa Leadership in the Community
-
Host Worldwide Webinar Series: Impact of Modeling & Simulation in Drug Development
Presentations from the pharmaceutical industry, academia, and regulatory agencies -
International Society of Pharmacometrics
Chair of the QSP Special Interest Group
Member of the Variability, Uncertainty, and Error in QSP Models Working Group
Co-Chair of the Integrating QSP and Machine Learning Working Group
Member of the Immuno-Oncology Working Group
Former Member of the QSP Workflows and Methodologies Working Group
Former Chair of the QSP in Regulatory Interactions Working Group
Former Secretary of the QSP SIG -
Strategic Cooperation Agreement with MathWorks®, provider of MATLAB®, and SimBiology®
Recent Highlights
Meet with Matt Marano, Chief Commercial Officer of Rosa & Co., to learn more about Rosa’s PhysioPD® Research Platforms at the MarcusEvans Evolution Summit in Montreux, Switzerland, on April 20-21, 2023. For more information about the summit, see ... Read More
Rosa is seeking PhD students, postdoctoral scholars, and early researchers in academia & industry to present as part of the Rosa World Wide Webinar series. These webinars will support outstanding early career investigators by providing an opportu... Read More
Rosa & Co. announced today the publication of an article titled, “From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology (QSP) Modeling in Cancer Immunotherapy,” which was published online ahead of p... Read More
Upcoming Events
-
MarcusEvans Pharma Marketing Summit
September 13-14, 2021http://www.pharmamarketingsummit.com/Boston, MA -
American Conference on Pharmacometrics (ACoP)
November 8-12, 2021https://www.go-acop.org/Virtual -
International Congress of Inborn Errors of Metabolism
November 21-23, 2021https://www.iciem2021.com.au/Virtual and Sydney, Australia
Recent Events
-
Population Approach Group in Europe (PAGE)
September 2-7, 2021http://go-isop.org/event/page-2/Virtual -
International Society of Pharmacometrics Virtual Quantitative Systems Pharmacology Week
August 16-20, 2021http://go-isop.org/event/international-society-of-pharmacometrics-virtual-quantitative-systems-pharmacology-week-2021/Virtual -
American Society of Clinical Oncology (ASCO)
June 4-8, 2021https://conferences.asco.org/am/dates-knowVirtual
The Rosa & Co. Executive Team
-
Ron Beaver, PhD
Founder, Chairman, and CEO
Dr. Beaver has over 25 years of experience in the drug–disease modeling industry. Prior to creating Rosa & Co. in 2002, Dr. Beaver collaborated with a global pharmaceutical firm to structure their open-source drug development group. In 1997, Dr. Beaver cofounded Pharsight Consulting Services, a first-generation pharmaceutical modeling company that drove large-scale adoption of leading-edge drug–disease modeling worldwide. Previously, Dr. Beaver was a principal of Pope Street Group (PSG), a...
Read MoreDr. Beaver has over 25 years of experience in the drug–disease modeling industry. Prior to creating Rosa & Co. in 2002, Dr. Beaver collaborated with a global pharmaceutical firm to structure their open-source drug development group. In 1997, Dr. Beaver cofounded Pharsight Consulting Services, a first-generation pharmaceutical modeling company that drove large-scale adoption of leading-edge drug–disease modeling worldwide. Previously, Dr. Beaver was a principal of Pope Street Group (PSG), a management consultancy and venture incubator firm. PSG incubated StarMine, a unique quantitative-modeling financial services company (subsequently acquired by Thomson Reuters). Prior to PSG, Dr. Beaver was an associate at Strategic Decisions Group (SDG). In the early 1990s, he closely observed the advancement of predictive biosimulation software which led to the spin-off of Entelos, Inc., the first-generation PhysioPD-style company (acquired by Rosa in 2014). Dr. Beaver holds a PhD in Engineering from Stanford University and a BA from Simpson College, on whose Board of Trustees he served.
Collapse -
Christina Friedrich, PhD
Chief Engineer, PhysioPD
Dr. Friedrich brings over 17 years of leadership expertise in applying mathematical models of biologic/physiologic systems for overcoming development challenges faced by pharmaceutical and consumer product companies. At Rosa (and previously at Entelos, Inc.), she has developed significant experience in the fields of diabetes, blood disorders, CNS disorders, oncology, immuno-oncology, rheumatoid arthritis, respiratory diseases, skin diseases, gastrointestinal disorders, and other immune system dy...
Read MoreDr. Friedrich brings over 17 years of leadership expertise in applying mathematical models of biologic/physiologic systems for overcoming development challenges faced by pharmaceutical and consumer product companies. At Rosa (and previously at Entelos, Inc.), she has developed significant experience in the fields of diabetes, blood disorders, CNS disorders, oncology, immuno-oncology, rheumatoid arthritis, respiratory diseases, skin diseases, gastrointestinal disorders, and other immune system dysfunctions and inflammatory processes. While at Rosa, Dr. Friedrich developed and published the first peer-reviewed journal article on the qualification of mechanistic mathematical models. Before Rosa, Dr. Friedrich was the Director of Core Product Development at Entelos, Inc., the first-generation leader in PhysioPD-style models. Dr. Friedrich has spearheaded numerous modeling methodologies and contributed to foundational patents, including on the use of virtual patients and populations to explore biological variability and uncertainty, and on the identification of biomarkers. Dr. Friedrich completed her BS at MIT and a PhD in Management Science and Engineering at Stanford University.
Collapse -
Mike Reed, PhD
Chief Scientist, PhysioPD
Dr. Reed brings 15 years of experience managing large-scale strategic collaborations with client pharmaceutical and consumer product organizations. At Rosa (and previously at Entelos, Inc.), his areas of expertise include metabolic diseases, oncology, central nervous system diseases, and inflammation/immunology. His efforts focus on trial design, target evaluation, competitive differentiation, and novel biomarkers, and has led to several patents and publications. Dr. Reed’s work has been presen...
Read MoreDr. Reed brings 15 years of experience managing large-scale strategic collaborations with client pharmaceutical and consumer product organizations. At Rosa (and previously at Entelos, Inc.), his areas of expertise include metabolic diseases, oncology, central nervous system diseases, and inflammation/immunology. His efforts focus on trial design, target evaluation, competitive differentiation, and novel biomarkers, and has led to several patents and publications. Dr. Reed’s work has been presented at dozens of scientific conferences worldwide. Prior to his position at Entelos, Dr. Reed held positions in preclinical pharmacology and drug development at Shaman Pharmaceuticals Inc. and Tularik Inc. (acquired by Amgen Inc.). His contributions include the development of novel animal models for type 2 diabetes. Dr. Reed completed his BS in Biology and MA in Exercise Physiology at The University of Texas at Austin, and a PhD in Exercise Physiology at The Ohio State University. He completed his postdoctoral fellowship at Stanford University, which focused on the mechanistic evaluation of insulin resistance in animal models.
Collapse -
Rebecca A. Baillie, PhD
Principal Scientist, Chief of Staff
Dr. Baillie is considered to be one of the leading experts in the field of lipid metabolism, and brings more than two decades of experience in mechanistic physiologic modeling in nearly all disease areas. Prior to Rosa, she was the Senior Research Biologist at Lipomics Technologies Inc., leading efforts in biomarker identification and drug development. Previously, at Entelos, Inc. Dr. Baillie focused on obesity research and the innovative Adipocyte CytoLab™, a cell-specific simulation model. Sh...
Read MoreDr. Baillie is considered to be one of the leading experts in the field of lipid metabolism, and brings more than two decades of experience in mechanistic physiologic modeling in nearly all disease areas. Prior to Rosa, she was the Senior Research Biologist at Lipomics Technologies Inc., leading efforts in biomarker identification and drug development. Previously, at Entelos, Inc. Dr. Baillie focused on obesity research and the innovative Adipocyte CytoLab™, a cell-specific simulation model. She also served as scientific lead in the collaboration with Zen-Bio Inc. to conduct research for new obesity therapeutics. Dr. Baillie was a research associate at the University of Texas at Austin, and a postdoctoral researcher at the University of Colorado and Colorado State University. Her research has culminated in more than 50 publications and submitted patents. Dr. Baillie earned a PhD from the University of Iowa in Human Nutrition, and an MS in Nutrition and BS in Nutrition Science from the University of California at Davis.
Collapse -
Matt Marano
Chief Commercial Officer
Mr. Marano has over 30 years of experience in the life sciences industry, both as a researcher and as a sales and business development professional. Prior to joining Rosa in 2017, Mr. Marano held worldwide business development leadership roles at SolveBio, a developer of actionable information assets that drive precision medicine, and Gen9 (now part of Ginkgo Bioworks), a leading synthetic biology solutions provider. Prior to Gen9, Mr. Marano created and expanded the global commercial presence...
Read MoreMr. Marano has over 30 years of experience in the life sciences industry, both as a researcher and as a sales and business development professional. Prior to joining Rosa in 2017, Mr. Marano held worldwide business development leadership roles at SolveBio, a developer of actionable information assets that drive precision medicine, and Gen9 (now part of Ginkgo Bioworks), a leading synthetic biology solutions provider. Prior to Gen9, Mr. Marano created and expanded the global commercial presence for a number of industry-leading life sciences firms, including Archimedes Inc. (acquired by Evidera), BioTrove’s RapidFire business unit (now part of Agilent Technologies Inc.), Ardais Corporation, and Molecular Dynamics. Mr. Marano began his career as a bench scientist at BASF Bioresearch Corporation (now part of AbbVie), and was a member of the development team for Humira®, one of a class of medications called biological response modifiers. Mr. Marano received his BS in Biology from Providence College, and completed graduate-level course work in Molecular Biology at Providence College and Harvard University Extension School.
Collapse -
Robert W. Singer
Principal, Rosa ForecastMD
Rob Singer brings over 20 years of experience in the healthcare market research field to Rosa & Co. Prior to joining Rosa in 2020, Rob conducted market research projects for Biotech, Pharmaceutical, Medical Device and Diagnostic Companies with Promedica and Cello Health Insight. During that time, Rob had the opportunity to partner with Bill Brastow on numerous Rosa ForecastMD projects for Promedica and Cello clients. Before moving into market research, Rob began his career in hospital and fi...
Read MoreRob Singer brings over 20 years of experience in the healthcare market research field to Rosa & Co. Prior to joining Rosa in 2020, Rob conducted market research projects for Biotech, Pharmaceutical, Medical Device and Diagnostic Companies with Promedica and Cello Health Insight. During that time, Rob had the opportunity to partner with Bill Brastow on numerous Rosa ForecastMD projects for Promedica and Cello clients. Before moving into market research, Rob began his career in hospital and field sales positions for Rhone-Poulenc Rorer (now Sanofi) and Forest Pharmaceuticals (now Allergan). Rob received his BS in Marketing from San Francisco State University and is based in the San Francisco Bay Area.
Collapse